Lantheus secures FDA fast track designation for prostate cancer drug
April 24, 2023 -- Lantheus Medical Imaging parent company Lantheus Holdings and partner Point Biopharma Global have secured fast-track designation from the U.S. Food and Drug Administration (FDA) for lutetium-177 PNT2002, a radiopharmaceutical for the treatment of metastatic, castration-resistant prostate cancer. Read More
Viewray posts 2023 Q1 revenue increases
April 13, 2023 -- Viewray posted revenue increases in its first quarter and outlined strategic business alternatives it is exploring to "maximize shareholder value." Read More
FDA clears Fusion's targeted alpha therapy
April 13, 2023 -- Fusion Pharmaceuticals has secured clearance from the U.S. Food and Drug Administration (FDA) for its radiopharmaceuticals actinium-225-FPI-2068 and corresponding imaging analog Indium-111-FPI-2107. Read More
Perimeter secures contract with healthcare marketing agency QooQoo
April 10, 2023 -- Perimeter Medical Imaging AI has inked an agreement with healthcare marketing agency QooQoo to market Perimeter's S-Series optical coherence tomography device. Read More
Orbit, Evergreen to collaborate on new radiopharmaceuticals
April 3, 2023 -- Orbit Discovery and Evergreen Discovery plan to collaborate on identifying cell-targeting peptides in order to develop new radiopharmaceuticals. Read More
Ablaze secures peptide drug license from RayzeBio
March 31, 2023 -- Ablaze Pharmaceuticals has licensed a peptide drug candidate from RayzeBio that it will develop to target the liver cancer biomarker GPC3. Ablaze plans to market the new drug in China, where the company is headquartered. Read More
Accuray highlights prostate cancer treatment trial results
March 27, 2023 -- Accuray is highlighting clinical results that show that, compared to surgery, stereotactic body radiation therapy better preserves urinary continence and sexual function in men with localized prostate cancer. Read More
Telix gets FDA nod for gallium injection prep kit
March 16, 2023 -- The U.S. Food and Drug Administration (FDA) has cleared Telix Pharmaceuticals' gallium-68 (Ga-68) gozetotide injection (Illuccix) preparation kit. Read More
Curium confirms no supply challenges for Eclipse trial
March 16, 2023 -- Nuclear medicine company Curium confirmed in a recent statement that it doesn't expect supply challenges of its lutetium-177 prostate-specific membrane antigen with 3-iodo-D-tyrosine for the company's Eclipse phase III clinical trial. Read More
ASTRO: Radiation oncology workforce appears stable
March 8, 2023 -- The U.S. radiation oncology workforce is expected to remain stable through 2030, according to a report published March 8 in the International Journal of Radiation Oncology, Biology, Physics. Read More
Special Feature
Representation in radiation oncology remains challenging

Radiation oncology has some of the lowest numbers when it comes to female senior faculty representation, according to research published in JAMA Network Open. Read more